Abstract | Coeliac disease, an inflammatory disease of the small intestine, shares key features with autoimmune disorders, such as susceptibility genes, presence of autoantibodies and T cell-mediated destruction of specific cells. Strikingly, however, continuous exposure to the exogenous dietary antigen gluten and gluten-specific adaptive immunity are required to maintain immunopathology. These observations challenge the notion that autoimmunity requires adaptive immune activation towards self antigens. Using coeliac disease as an example, we propose that other exogenous factors might be identified as drivers of autoimmune processes, in particular when evidence for T cells with specificity for self antigens driving the disease is lacking.
Immune processes that lead to tissue destruction and disease need to be initiated and then maintained. Thus, conceivably, there can be separate triggers and drivers of these processes. A trigger can be defined as an event that activates the disease process in some way, whereas a driver can be defined as a factor that powers and maintains the disease. We generally assume that in an organ-specific autoimmune disorder the triggers are exogenous factors that break self-tolerance by the induction of innate immune responses and the activation of dendritic cells, whereas drivers are self antigens that activate adaptive immunity. Exogenous factors are thought to drive the adaptive immune response in the context of molecular mimicry, when T cells that recognize the exogenous antigen cross-react with self antigens that are the real drivers of the disease. Thus, exogenous antigens are not typically considered to be drivers of autoimmune disorders.
Coeliac disease, which has key features of autoimmune disorders, challenges this view. It was first described by the Greek physician Aretaeus, who lived around the first century AD, as an intestinal disorder that is associated with malabsorption and diarrhoea. In the 1940s, the Dutch paediatrician Willem-Karel Dicke discovered that coeliac disease is caused by the consumption of cereal gluten proteins 1, 2 (BOX 1). Later, it was found that the fingerlike projections of the small bowel mucosa, the intestinal villi, are absent in patients with coeliac disease who consume gluten 3 . This explains why patients can suffer from malabsorption. The condition is common, with a prevalence of about one in 100, and it occurs selectively in individuals expressing HLA-DQ2 or HLA-DQ8 (REF. 4 ). The presence of transglutaminase 2 (TG2)-specific autoantibodies 5 , which are unique to patients with coeliac disease, enables the diagnosis of the disease. Similar to patients with organ-specific autoimmune disorders, patients with coeliac disease have autoantibodies and suffer from the destruction of a specific tissue cell type by CD8 + T cells. However, we also know that these autoimmune features require the presence of gluten and that HLA-DQ2-or HLA-DQ8-restricted gluten-specific CD4 + T cell responses have a central role in disease pathogenesis (FIG. 1) .Therefore, we propose that, on the basis of coeliac disease, we should consider the possibility that exogenous antigens can drive autoimmune disorders.
In this Opinion we discuss the key genetic and immunological features of coeliac disease in the context of an unknown driver. We also dissect how gluten and the gluten-reactive CD4 + T cell response drive the autoimmune processes that are characteristic of coeliac disease. Finally, we contrast the roles of drivers and triggers in the pathogenesis of coeliac disease and discuss the relevance of these concepts for understanding autoimmunity in general.
Autoimmune features of coeliac disease
Considering the key genetic and immunological features of coeliac disease, it becomes apparent that if we did not know that coeliac disease relates to gluten consumption, we would classify it as a typical organspecific autoimmune disorder that targets the small intestine.
Genetics. Similar to other autoimmune diseases, coeliac disease is a polygenic disorder for which the MHC locus is the single most important genetic factor. The MHC locus accounts for 40-50% of the genetic variance in the disease. Coeliac disease has a very strong HLA association. The majority of patients carry a particular variant of HLA-DQ2 (DQA1*05:01, DQB1*02:01; also known as DQ2.5). Those who are not DQ2.5 + almost all carry HLA-DQ8 (DQA1*03, DQB1*03:02) or they carry another variant of HLA-DQ2 (DQA1*02:01, DQB1*02:02; also known as DQ2.2) 6 . As all patients with coeliac disease carry particular HLA variants, HLA can be considered a necessary, but not a sufficient, factor for disease development. HLA testing is regularly used in the clinic to exclude the diagnosis of coeliac disease.
Several non-MHC genes have also recently been discovered as susceptibility factors in coeliac disease. So far, 39 loci with 57 independent association signals have been described 7 . Many of these loci harbour genes that are related to the immune response, particularly to B cell and T cell function. Together, these loci have been estimated to account for 14% of the genetic variance of the disease 7 . Interestingly, many of the susceptibility loci for coeliac disease are shared with those for autoimmune diseases Nature Reviews | Immunology [8] [9] [10] [11] [12] . Typically, disease-associated single-nucleotide polymorphisms (SNPs) locate to regulatory DNA marked by DNase I hypersensitive sites (DHSs) 13 . These SNPs often affect the recognition of gene enhancers by transcription factors, thereby resulting in differences in gene expression. The implicated transcription factors are part of regulatory networks that seem to be shared between coeliac disease and other auto immune diseases 13 . For example, of the SNPs associated with autoimmune disorders that fall within DHSs, one-quarter localize to recognition sequences of transcription factors that interact with interferon-regulatory factor 9 (IRF9). This indicates that Janus kinase (JAK)-signal transducer and activator of transcription (STAT)-mediated type I interferon (IFN) responses might have important roles in mediating diverse autoimmune disorders. The sharing of genetic loci between coeliac disease and other autoimmune diseases indicates that there might be shared immunological mechanisms and shared autoimmune features.
Autoantibodies.
Patients with active coeliac disease produce autoantibodies, mainly specific for TG2 (REF. 5) , and the assessment of such autoantibodies has an increasingly important role in clinical practice
. The production of autoantibodies is a typical feature of many autoimmune diseases, such as anti-neutrophil cytoplasmic antibodies (ANCAs) in vasculitis 14 and anti-citrulline protein antibodies (ACPAs) in rheumatoid arthritis 15 . TG2 is an enzyme with many functions, one of which involves modifying gluten peptides as a substrate
. In coeliac disease, antibodies that are specific for TG2 are produced locally in the mucosa 16 and possibly elsewhere. Plasma cells producing TG2-specific antibodies were recently visualized in coeliac disease lesions and isolated by using labelled TG2 antigen 17 . On average, 10% of the plasma cells of a disease lesion are TG2-specific cells, and most produce IgA. The TG2-specific plasma cells disappear when the patients commence a gluten-free diet. Monoclonal antibodies generated from single plasma cells recognize conformational epitopes of gluten, have restricted usage of variable heavy (VH) and variable light (VL) chain gene segments and also have few somatic hypermutations 17 . This could indicate that the antibodies are generated without the involvement of T cells. However, the strict occurrence of TG2-specific antibodies in individuals with certain HLA types 18 , and the fact that the avidity of the antibodies decreases by reverting them to presumed germline configuration 17 , indicate that such antibodies have undergone affinity maturation and that their development is T cell dependent.
The strict correlation between HLA type and the presence of autoantibodies is also observed in several other autoimmune disorders. In rheumatoid arthritis, there is a strong association between the HLA-DRB1 shared epitope and ACPAs 19 . It was recently reported that ANCA-associated vasculitis consists of two genetically distinct subsets: myeloperoxidase-specific ANCAs, which are primarily associated with HLA-DQ polymorphisms, and proteinase 3-specific ANCAs, which are primarily associated with HLA-DP polymorphisms 14 . These associations of HLA types with distinct autoantibodies indicate that there are specific T cells that control autoantibody formation.
Leukocyte infiltration. Autoimmune lesions are often characterized by the accumulation of leukocytes. Likewise, coeliac disease lesions have an infiltration of leukocytes, both in the epithelium and in the lamina propria 20 . In the epithelium, the infiltration of CD8 + T cells, termed intraepithelial cytotoxic T lymphocytes (IE-CTLs), dominates. In the lamina propria, there is an increased density of many cell types, including plasma cells, CD4 + T cells and antigen-presenting cells.
Tissue destruction. Similar to type 1 diabetes, in which β-islet cells of the pancreas are the only cell type affected, coeliac disease is characterized by the selective destruction of intestinal epithelial cells. The basal membrane of the epithelium remains intact and there are no tissue ulcerations 21 . The targeting of a specific cell type in coeliac disease implies
Box 1 | Gluten proteins and coeliac disease
Gluten is the collective name for the storage proteins that are found in grains of wheat, barley and rye 100 . The name gluten comes from the cohesive and elastic ball of proteins that remains after kneading and washing wheat flour in water to remove the starch. Grain proteins in wheat, barley and rye are very similar, and although the gluten ball can only be formed from flour of wheat, the term gluten is often used to name all of these types of protein. Typically, gluten proteins are rich in glutamine and proline residues. Their high proline content makes them resistant to gastrointestinal digestion. In wheat, gluten proteins are divided into gliadins and glutenins, whereas the gluten proteins of barley and rye are termed hordeins and secalins, respectively. Patients with coeliac disease raise CD4 + T cell responses against several distinct gluten peptides and these peptides are recognized in the context of coeliac disease-associated HLA-DQ molecules 38 . In addition, patients make antibodies specific for gluten proteins.
Figure 1 | Autoimmune phenomena and gluten-specific adaptive immunity are associated with coeliac disease and are dependent on gluten exposure. Coeliac disease pathology is characterized by the presence of gluten-specific adaptive immunity and by the presence of autoimmune phenomena, such as cytotoxic autoantibodies and CD8 + T cells (intraepithelial cytotoxic T lymphocytes (IE-CTLs)) that mediate enterocyte destruction without being gluten specific. Autoimmune and non-autoimmune phenomena, as well as tissue pathology, recede when dietary gluten is eliminated and reoccur when gluten is reintroduced.
that specific receptor-ligand inter actions are involved. In coeliac disease, intestinal epithelial cells (enterocytes) express nonclassical MHC class I molecules that are recognized by activating natural killer (NK) cell receptors, which are upregulated on IE-CTLs [22] [23] [24] . The two most highly expressed NK cell receptors are natural killer group 2, member D (NKG2D) and CD94-NKG2C, which recognize MHC class I polypeptiderelated sequence (MIC) and HLA-E molecules that are induced on epithelial cells of patients with coeliac disease 24, 25 . NKG2D and MIC (and related molecules) have also been implicated in the pathogenesis of rheumatoid arthritis and type 1 diabetes 26, 27 . Furthermore, levels of interleukin-15 (IL-15), a cytokine that is upregulated in tissue cells that are targeted by an autoimmune process [28] [29] [30] , are increased in the epithelium of patients with coeliac disease 31 . IL-15 functions in a cell contact-dependent manner to increase NKG2D expression on IE-CTLs and also functions as a co-stimulatory molecule for the T cell receptor (TCR) and NK cell receptors 23, 32 . Together, the alterations observed at the level of intestinal epithelial cells and IE-CTLs in coeliac disease lead to dysregulated activation of IE-CTLs and villous atrophy. The two non-mutually exclusive mechanisms proposed for intestinal epithelial cell destruction in coeliac disease are direct NK cell receptor-mediated destruction on the basis of the recognition of inducible non-classical MHC molecules, and, potentially, TCR-mediated killing through the recognition of low avidity (self) antigens, as a result of a decrease in the TCR activation threshold 33, 34 . In both cases, epithelial cells are destroyed by IE-CTLs with autoreactive properties that recognize self or modifiedself antigens through activating NK cell receptors and/or the TCR 4 .
Thus, coeliac disease has many of the features that classify disorders as auto immune (FIG. 2) . In keeping with the research frontiers of other autoimmune diseases, primary research objectives in coeliac disease would probably be to identify TG2-reactive T cells and to understand why T cell tolerance to TG2 is broken. However, this has not been the case and coeliac disease does not often feature on lists of autoimmune conditions. Instead, it is generally perceived as a food hypersensitivity disorder for which gluten is the culprit food antigen. In one way this is true: gluten is the driver of the condition.
Gluten: the driver of coeliac disease The gut lesions of most patients with coeliac disease completely normalize when gluten is excluded from the diet, and they reappear when the patients eat gluten again. Both the presence of autoantibodies specific for TG2 and the increased number of IE-CTLs are gluten dependent, as they change after gluten elimination or challenge 35, 36 (FIG. 1) . Patients with coeliac disease, but not healthy controls, have HLA-DQ2-or HLA-DQ8-restricted CD4 + T cells in the gut mucosa that are reactive to gluten 37 . Given the strong HLA association, CD4 + T cells are probably key players in the development of the disease.
HLA-DQ-restricted and gluten-specific CD4
+ T cell response. Gluten-reactive T cells are present in the lamina propria of patients with coeliac disease and preferentially recognize deamidated gluten peptides 38 in the context of disease-associated HLA molecules, but not in the context of other HLA molecules 39, 40 (FIG. 3) . In these deamidated peptides, certain glutamine residues have been converted to glutamate by the enzymatic action of TG2 (REFS 41, 42) . The presentation of negatively charged peptides to T cells might explain the association of HLA-DQ2 and HLA-DQ8 molecules with the disease, as both of these MHC molecules have preference for binding to peptides with negatively charged anchor residues 43 . Not only T cells, but also antibodies, of patients with coeliac disease preferentially recognize deamidated gluten peptides 44 . The situation of having antibodies specific for both the enzyme that mediates a post-translational modification and the modified product itself is paralleled in rheumatoid arthritis. Patients with rheumatoid arthritis have antibodies that are specific for citrullinated antigens, as well as for the peptidylarginine deiminase (PAD) enzyme that mediates the citrullination process (reviewed in REF. 15 ). This might indicate that there are shared mechanisms for antibody formation in the two diseases.
The presence of a large number of proline residues in gluten renders it resistant to digestion by intestinal enzymes. Deamidation and the generation of long peptides provide an explanation as to why immunogenic peptides of gluten are produced 45 . Importantly, analysis of the cytokine profile of gluten-specific T cells has shown that they produce IFNγ (T helper 1 (T H 1) type immunity) and IL-21, but not IL-17 (REF. 46 ). Multiple types of immune reaction are probably required to create the lesions associated with coeliac disease, but the gluten-reactive CD4 + T cells
Box 2 | Autoantibodies and coeliac disease
Autoantibodies in coeliac disease were initially detected as reticulin-specific antibodies by staining of rat tissue 101, 102 . Subsequently, IgA endomysium-specific antibodies (EMAs), detected by staining of monkey oesophagus 103 or human umbilical cord 104 , were described. The main antigen recognized by reticulin-specific antibodies and EMAs was identified as the enzyme transglutaminase 2 (TG2) 5 . Autoantibodies specific for calreticulin 105 and actin 106 are also associated with active coeliac disease, but in contrast to TG2-specific antibodies these are not used in routine diagnostics. TG2-specific antibodies are found in serum as IgA, IgG and IgM isotypes. Assaying for TG2-specific IgA is most commonly used in clinical practice, as this test has the highest disease specificity and sensitivity 107 . In fact, the disease specificity and sensitivity for this test are higher than for any other autoantigen-disease association. Previously, the detection of histological changes in small intestinal biopsy samples, such as blunting of intestinal villi and infiltration of inflammatory cells, was considered mandatory for the diagnosis of coeliac disease. Biopsy examination is no longer mandatory in the diagnostic work-up of children 108 , mainly because of the very strong diagnostic performance of the autoantibody tests.
Box 3 | Biology of transglutaminase 2
Transglutaminase 2 (TG2) is a ubiquitously expressed enzyme with multiple functions 109 . It is found intracellularly bound to GTP and extracellularly bound to Ca
2+
. The Ca 2+ -associated form can modify specific glutamine residues in polypeptides by either crosslinking them with primary amines -and, when this is a lysine residue, forming protein crosslinks -or converting the glutamine residue to glutamate by reaction with water in a process termed deamidation 109 . Many gluten peptides are excellent substrates for TG2, which can lead to their post-translational modification 110 . The TG2 enzyme is inactivated by oxidation and can be made active again under reducing conditions 111 . The enzyme is not constitutively active in vivo 70 . The mechanisms underlying its activation are not fully understood, but evidence indicates that inflammation, tissue destruction and a reducing environment are associated with enzyme activity. As we discuss below, there is evidence that the autoimmune processes in coeliac disease can be driven by the activation of gluten-specific CD4 + T cells.
TG2-specific autoantibodies. The strict dependence on gluten exposure for the production of TG2-specific antibodies in coeliac disease 35 indicates that gluten is involved in driving the formation of these antibodies (FIG. 3) . A possible mechanism in keeping with this idea could be that gluten-reactive CD4 + T cells provide the required help to TG2-specific B cells in a hapten-carrier-like manner, by involvement of TG2-gluten complexes 49, 50 . Gluten peptides form covalent complexes when incubated with TG2, either through a thioester bond to the cysteine residue in the active site of TG2 (enzyme-substrate intermediate) or through an isopeptide bond to lysine residues of TG2 (REF. 51 ). When TG2-specific B cells bind and internalize such complexes through their surface immunoglobulin, deamidated gluten peptides can be released by proteolytic cleavage, or by cleavage of the isopeptide and thioester bonds in endosomes; deamidated gluten peptides can then bind HLA-DQ2 or HLA-DQ8 for presentation to gluten-reactive T cells. Some experimental support for this model has been obtained 17 . Further, assays measuring antibodies that are reactive with deamidated gliadin peptides are better predictors of disease than assays measuring antibodies that are reactive with native gliadin peptides 52 . This suggests that B cells that are specific for the post-translationally deamidated peptides may receive help from the same gluten-specific T cells that provide help to TG2-specific B cells. Of note, TG2-specific, as well as gluten-specific, B cells can function as antigen-presenting cells for gluten-specific T cells, and in this way serve as important amplifiers of the CD4 + T cell response to gluten.
IE-CTL activation.
The proliferation and activation of IE-CTLs require the presence of gluten and parallel the activation of gluten-specific CD4 + T cells (FIG. 3) . When patients start a gluten-free diet, the number of IE-CTLs usually returns to normal, expression of NK cell receptors on IE-CTLs decreases and expression of non-classical MHC class I molecules on epithelial cells is downregulated [22] [23] [24] . We have proposed that the licensing of IE-CTLs to kill requires two independent but related alterations in the intestinal mucosa: activated gluten-specific CD4 + T cells, and a stressed epithelium expressing high levels of IL-15 and non-classical MHC class I molecules 25, 53 . It remains to be determined how epithelial stress, adaptive gluten-specific T cell and B cell immunity and activation of TG2 might interplay to determine the acquisition of a killer phenotype by IE-CTLs.
Triggers of coeliac disease
With respect to the concept of triggers and drivers, if gluten is the driver of coeliac disease, are there also triggers implicated in this disease? There is no experimental evidence to indicate that gluten could promote the activation of autoreactive T cells through molecular mimicry, as has been proposed for other triggers of autoimmunity 54, 55 , such as coxsackie virus triggering autoimmune myocarditis 56 . Nonetheless, could there be other triggers that help to initiate the CD4 + T cell response to gluten and that induce alterations in epithelial cells that contribute to the activation of IE-CTLs? The need for a trigger. HLA is a necessary, but not a sufficient, genetic factor in coeliac disease, which indicates that additional factors are required for disease development. In particular, the poor digestion of gluten peptides and their deamidation by TG2 provide an explanation as to why immunogenic gluten peptides of relatively high affinity for HLA-DQ2 and HLA-DQ8 are generated. However, this does not explain why inflammatory T cell responses instead of regulatory T cell responses are mounted against gluten in the intestinal environment, which normally promotes tolerogenic responses to oral protein antigens 57 . In a mouse model in which IL-15 is overexpressed in the lamina propria to levels similar to those found in patients with active coeliac disease, IL-15 in conjunction with retinoic acid was shown to disrupt oral tolerance and to induce the differentiation of inflammatory dendritic cells that produce IL-12p70, and it also promoted the differentiation of IFNγ-producing T cells (T H 1 type immunity) 58 . Type I IFNs are also upregulated in the intestinal mucosa of patients with active coeliac disease 59 , although the increased levels are moderate and are lower than those in the skin lesions of patients with systemic lupus erythematosus 60 . Type I IFNs could potentially be a component of an alternative pathway causing a loss of tolerance to gluten, through their ability to activate dendritic cells, promote T H 1 type immunity and induce loss of oral tolerance. Furthermore, the enzyme TG2 is not constitutively active in vivo, but inflammation is associated with activation of this enzyme
. Finally, another key aspect of coeliac disease is the upregulation of IL-15 and non-classical MHC class I molecules in the epithelium. It is probable that the CD4 + T cell response has a role, but it is not sufficient alone to induce these alterations in the intestinal epithelium. Together, these observations are in line with the concept that a strong adaptive immune response is typically paired with an innate component that facilitates the adaptive response 61 (FIG. 3) . What might such innate factors be in coeliac disease?
Gluten as a trigger as well as a driver?
The simplest model would be that gluten is also a trigger with innate properties. As discussed above, two mechanisms have been suggested to explain the induction of inflammatory T cell responses to gluten through the activation of dendritic cells: the first mechanism involves IL-15 upregulation in the lamina propria 58 and the second mechanism involves type I IFNs 62 (FIG. 3) .
Gluten has been shown to promote the upregulation of IL-15 (REF. 63 ) and possibly IFNα 62 in the lamina propria by unknown mechanisms. In addition to inducing innate cytokines that alter the tolerogenic phenotype of dendritic cells, studies indicate that gluten might also have a role in the effector destructive phase of the disease by activating epithelial cells 63, 64 and by promoting the upregulation of IL-15 and non-classical MHC class I molecules on intestinal epithelial cells 22, 65 . However, the literature on 'innate properties' of gluten is heterogeneous and conflicting, and there is no consensus on the mechanisms by which gluten could trigger innate immune responses (discussed in REF. 25 ). It was recently shown that innate immune stimulation by wheat proteins might not be mediated by gluten proteins themselves, but rather by wheat amylase trypsin inhibitors, which co-purify with certain gluten proteins and which activate Toll-like receptor 4 (REF. 66 ). In addition, it is not clear why gluten might have innate effects only in certain individuals or what would determine it acquiring such properties in a given individual at a certain time. It is possible that this acquired 'sensitivity' to gluten requires the encounter between a predisposing genetic background and an environmental factor that renders host cells responsive to the innate properties of gluten. Thus, even supposing that gluten does have some innate properties, it would be difficult to explain the initiation and effector phases of the disease without the existence of triggers that would alter the microenvironment in such a way that gluten could induce the activation of the mucosal immune system. Such triggers could be viruses and bacteria of the gut.
Viruses and type I IFNs. Viral infections, in particular enteroviral infections, such as with rotavirus 67, 68 , have been suggested to increase the incidence of coeliac disease and other autoimmune disorders, such as type 1 diabetes 53, 69 . Furthermore, studies in mice using polyinosinic-polycytidylic acid (polyI:C) as a mimic for infection with a double-stranded RNA virus indicate that viral infections may promote activation of TG2 (REF. 70 ). Viral infections lead to the production of type I IFNs 53, 71 , which have immunostimulatory properties 72 ; therefore, we assume that viral infections might trigger autoimmune disorders as a consequence of type I IFN induction. Type I IFNs could also be induced by bacterial infections [73] [74] [75] [76] and, potentially, by as yet undefined host factors that are not related to infections. Future studies will establish the role of type I IFNs and other virus-induced innate factors in coeliac disease pathogenesis (FIG. 3) . We also need to investigate how type I IFNs could remain upregulated in the intestinal mucosa of patients with coeliac disease and how their production could become gluten dependent once viruses have been cleared. Unless chronic viral infections are involved, it would seem that viral infections might be responsible for triggering the initial type I IFN induction, but that other, as yet undefined, factors are responsible for maintaining increased type I IFN levels in the intestinal mucosa. How gluten could contribute to the upregulation of type I IFNs remains to be determined.
Microbiota.
Complex disorders result from the interaction between environmental factors, the microbiota and the immune status of the host. The increase in the incidence of autoimmune disorders over the past few decades cannot be explained by genetic drift and is instead thought to be the result of changes in the environment. It is now recognized that the microbiota can affect intestinal immune homeostasis and the health of epithelial cells [77] [78] [79] . Short chain fatty acids that are produced by the microbiota promote epithelial cell proliferation through the activation of G protein-coupled receptors and might affect the intestinal immune system through their histone deacetylase inhibitory properties 113 . Furthermore, the intestinal microbiota comprises bacteria that promote regulatory immune responses (symbionts) and bacteria that promote inflammatory immune responses (pathobionts) [77] [78] [79] . As for other autoimmune disorders, such as type 1 diabetes, multiple sclerosis and rheumatoid arthritis 80, 81 , differences in the composition of the microbiota of patients with active coeliac disease have been reported compared with healthy controls [82] [83] [84] [85] [86] . Alterations were also reported for patients on a gluten-free diet 82, 83, 85, 86 . In particular, decreases in butyrate-producing bacteria Faecalibacterium prausnitzii and representatives of the genus Bifidobacterium were reported in patients with coeliac disease 87, 88 , as well as an expansion of potentially pathogenic bacterial populations, such as Escherichia coli and Staphylococcus spp. [89] [90] [91] . It remains to be determined whether these changes are a consequence of the presence of an inflammatory milieu or whether they have an active role in causing disease (FIG. 3) . Additional studies are required to assess whether dysbiosis might constitute a trigger for loss of tolerance to gluten and full licensing of IE-CTLs.
Altogether, although there is strong support for the role of microorganisms as triggers of innate immune activation, there is no evidence of a role for molecular mimicry in coeliac disease. In other words, we do not yet have any evidence that coeliac disease pathogenesis is the result of a T cell response against a microbial peptide that is cross-reactive with gluten. For example, it has been proposed that adenoviruses might contain sequences shared with gluten 92 , but the presence of T cells that are crossreactive with gluten and adenovirus could not be identified. Actually, coeliac disease also illustrates that there is no need to invoke molecular mimicry to explain loss of tolerance 93 . However, although individual potential culprits have been identified, we still have a long way to go before demonstrating how a microorganism in the context of a particular genetic background might trigger disease through the induction of IL-15 or the production of type I IFNs.
Conclusions and perspective
Analysing the drivers of coeliac disease leads us to conclude that an exogenous antigen (gluten) can result in the induction of autoimmune features, such as autoantibodies, and the destruction of a specific tissue type. We hence propose that the adaptive immune response in an autoimmune disease does not need to be directed at, or even related to, the antigens that are the target of the autoimmune process. Furthermore, analysis of coeliac disease pathogenesis also leads us to question the concept that the destruction of a specific cell type requires cognate TCR-peptide-MHC interactions. IE-CTLs destroy intestinal epithelial cells in coeliac disease on the basis of the presence of stress signals rather than because they are specific for an epithelial cell antigen. Only cells that upregulate IL-15 and nonclassical MHC class I molecules will be targeted by IE-CTLs. The receptor-ligand interactions involve non-cognate recognition of low affinity self or microbial peptides by the TCR, and recognition of inducible non-classical MHC class I molecules by NK cell receptors. Thus, the presence of CD8 + T cells with lymphokine-activated killer activity and/or a very low activation threshold in the tissue targeted by an autoimmune process could point to an exogenous factor as the driver.
These observations lead us to question how much we know about the drivers of other autoimmune diseases. Can we conclude with certainty that the driver is not, at least at some point, an exogenous factor, the role of which did not involve molecular mimicry? For example, it has been proposed that the driver of rheumatoid arthritis 94 and inflammatory bowel disease 95 might be a dysregulated immune response against the bacteria that compose our microbiota. In accordance with the microbiota being a driver of disease, mouse models of colitis require the presence of microbiota 96 , and in humans, antibiotic treatment 97 , as well as diverting the faecal stream away from sites of disease 98 , can reduce the activity of inflammatory bowel disease. Primary biliary cirrhosis is an interesting example in which a bacterium, Novosphingobium aromaticivorans, that shares antigenic epitopes with mitochondria is recognized by natural killer T cells and functions as the initial driver of the disease, before classical, autoreactive T cells take over 99 . Therefore, there may be a range of autoimmune disorders, with diseases in which exogenous antigens are the only driver at one end of the range, those in which exogenous antigens are the initial driver in the middle and diseases in which the immune response is selectively directed against self antigens at the other end. We argue that, when considering the pathogenesis of autoimmunity, thinking about drivers that might not be self antigens could be highly informative and could change the way we diagnose, prevent and treat autoimmune disorders. The identification of exogenous drivers in autoimmunity is a difficult but not an impossible task. Taking into account MHC association, post-translational modifications, the antigen and the tissue, it is possible to design strategies that will facilitate the identification of potential drivers of autoimmune disease outside the human proteome . The T cell receptor recognizes antigen as a complex of antigenic peptide bound to an MHC molecule, whereas B cell receptors and antibodies recognize antigen directly and with a higher affinity than the T cell receptor. Thus, antibodies are better suited than T cell receptors to identify their target antigens. Care should be taken to screen potential target antigens that are correctly folded to capture antibodies recognizing conformational determinants. For example, the epitopes of TG2 recognized by antibodies from patients with coeliac disease are conformational 17 . A third approach relates to the identification of antigenic peptides that bind to MHC molecules associated with disease, such as HLA-DQ8, which is associated with type 1 diabetes, and HLA-DR4, which is associated with rheumatoid arthritis. In coeliac disease, this approach has been used to identify T cell epitopes of gluten that are presented by the HLA-DQ2.5 and HLA-DQ2.2 molecules (L.M.S., E. Bergseng, M. Bodd, S. Dørum, L. E. Fallang, J. Stamnaes and G. A. de Souza, unpublished observations).
